Research

Cellular

Dulaglutide is associated with a significantly higher risk of overall hematologic malignancy (OR = 2.18, 95%CI = 1.14-4.19).

Clinicians should be cautious when prescribing dulaglutide due to its association with increased hematologic malignancy risk.

StrongSupportsmedium confidence
Dulaglutide showed a significantly higher risk of overall hematologic malignancy [odds ratio (OR) = 2.18, 95% confidence interval (95%CI) = 1.14-4.19).
Pao‐Yen Lin et al. · Biomolecules · 2025

Why this rating

Based on a pilot network meta-analysis of randomized controlled trials.

Source

Divergent Risks of Hematologic Malignancies Associated with GLP-1 Receptor Agonists and SGLT2 Inhibitors: Preliminary Findings from a Pilot Network Meta-Analysis

Pao‐Yen Lin et al. · Biomolecules · 2025

DOI 10.3390/biom15111622

Meta-analysisCited 5×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →